SLC7A5 is required for cancer cell growth under arginine-limited conditions
Cell Reports · 2025-01 · 44 (1) · 115130
DOI: 10.1016/j.celrep.2024.115130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025-01. Verfasst von Kyle N Dunlap und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Utah, Salt Lake City, UT 84112, USA. Hauptthemen laut MEDLINE: Arginine, Large Neutral Amino Acid-Transporter 1, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Tumor cells must optimize metabolite acquisition between synthesis and uptake from a microenvironment characterized by hypoxia, lactate accumulation, and depletion of many amino acids, including arginine. We performed a metabolism-focused functional screen using CRISPR-Cas9 to identify pathways and factors that enable tumor growth in an arginine-depleted environment. Our screen identified the SLC-family transporter SLC7A5 as required for growth, and we hypothesized that this protein functions as a high-affinity citrulline transporter. Using isotope tracing experiments, we show that citrulline uptake and metabolism into arginine are dependent upon expression of SLC7A5. Pharmacological inhibition of SLC7A5 blocks growth under low-arginine conditions across a diverse group of cancer cell lines. Loss of SLC7A5 reduces tumor growth and citrulline import in a mouse tumor model. We identify a conditionally essential role for SLC7A5 in arginine metabolism, and we propose that SLC7A5-targeting therapeutic strategies in cancer may be effective in the context of arginine limitation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Biochemistry, University of Utah, Salt Lake City, UT 84112, USA; Howard Hughes Medical Institute, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
- Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Biochemistry, University of Utah, Salt Lake City, UT 84112, USA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: greg.ducker@biochem.utah.edu.
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- American Cancer Society
- U.S. Department of Defense
- Howard Hughes Medical Institute
- National Institutes of Health
- University of Utah
Zitieren
APA
Dunlap, K. N., Bender, A., Bowles, A., Bott, A. J., Tay, J., Grossmann, A. H., Rutter, J., & Ducker, G. S. (2025). SLC7A5 is required for cancer cell growth under arginine-limited conditions. Cell Reports, 44(1), 115130. https://doi.org/10.1016/j.celrep.2024.115130
Vancouver
Dunlap KN, Bender A, Bowles A, Bott AJ, Tay J, Grossmann AH, et al. SLC7A5 is required for cancer cell growth under arginine-limited conditions. Cell Reports. 2025;44(1):115130. doi:10.1016/j.celrep.2024.115130
BibTeX
@article{Dunlap2025,
author = {Dunlap, Kyle N and Bender, Austin and Bowles, Alexis and Bott, Alex J and Tay, Joshua and Grossmann, Allie H and Rutter, Jared and Ducker, Gregory S},
title = {SLC7A5 is required for cancer cell growth under arginine-limited conditions},
journal = {Cell Reports},
year = {2025},
volume = {44},
number = {1},
pages = {115130},
doi = {10.1016/j.celrep.2024.115130}
}
EUVIMED